Sun Pharmaceutical Industries Ltd

Sun Pharmaceutical maintains a conservative capital structure characterized by low leverage and strong liquidity. The debt-to-equity ratio stands at 0.06, indicating minimal reliance on debt financing relative to shareholder equity. The current ratio of 2.82 suggests ample short-term assets to cover liabilities, supported by cash and equivalents of 116.03 billion INR against long-term debt of 46.27 billion INR. This balance sheet composition provides a robust buffer against financial distress.

Profitability metrics demonstrate efficient capital utilization, with a return on equity of 13.74% and a return on assets of 10.55%. The company generated net income of 114.79 billion INR on revenue of 584.62 billion INR, reflecting a healthy net margin. Operating income of 122.46 billion INR further underscores strong operational efficiency before interest and taxes. These returns indicate that the company is effectively converting its asset base and equity into earnings.

There are no material changes to report for Sun Pharmaceutical Industries Ltd (SUN.NS) based on the available data. The analysis indicates no significant shifts in the company's profile compared to prior assessments, with no new events or developments identified in the monitored signals. The cross-source signal data shows zero dispatches per day across the observed period from late June through mid-July 2026. This absence of new information flow suggests a period of stability or lack of new public disclosures regarding the company's operations or financial status during this timeframe. Furthermore, the company's structural metrics remain static, with no recorded changes in officer count, analyst coverage, index membership, or top holder composition. The lack of updates in these key areas reinforces the conclusion that the company's fundamental landscape has not undergone any notable transformations recently. Consequently, there is no new material information to synthesize for investors or stakeholders. The current data set does not support any assertions of change in performance, strategy, or market perception for Sun Pharmaceutical Industries Ltd, indicating a continuation of the status quo as previously analyzed.

Revenue grew at a 10.9% CAGR over four years, reaching INR 584.6 billion in FY2026.

Net income surged with a 36.9% CAGR, hitting INR 114.8 billion in FY2026.

Analysts project 9.0% upside to a mean price target of INR 2,047.91.

Net debt to EBITDA stands at 7.69, indicating a high leverage band.

Interest coverage ratio is low at 1.73, suggesting limited buffer against interest costs.

Net income growth slowed to 5.0% year-over-year in FY2026.

Cash conversion ratio of 1.1 is below the cohort median of 1.2.

Revenue INR 146.12B, +12,8% YoY; Operating income +14,7% YoY.

• ▍Revenue INR 146.12B, +12,8% YoY
• ▍Operating income +14,7% YoY
• ▍Net income +26,2% YoY
• ▍Net margin 18.6%

Revenue INR 155.21B, +13,5% YoY; Operating income +10,1% YoY.

• ▍Revenue INR 155.21B, +13,5% YoY
• ▍Operating income +10,1% YoY
• ▍Net income +16,0% YoY
• ▍Net margin 21.7%

Revenue INR 144.78B, +8,9% YoY; Operating income +5,7% YoY.

• ▍Revenue INR 144.78B, +8,9% YoY
• ▍Operating income +5,7% YoY
• ▍Net income +2,6% YoY
• ▍Net margin 21.5%

Revenue INR 138.51B, +9,5% YoY; Operating income −14,9% YoY.

• ▍Revenue INR 138.51B, +9,5% YoY
• ▍Operating income −14,9% YoY
• ▍Net income −19,6% YoY
• ▍Net margin 16.5%

Revenue INR 129.59B; Operating income INR 23.99B.

• ▍Revenue INR 129.59B
• ▍Operating income INR 23.99B
• ▍Net margin 16.6%

Revenue INR 136.75B; Operating income INR 32.46B.

• ▍Revenue INR 136.75B
• ▍Operating income INR 32.46B
• ▍Net margin 21.2%

Revenue INR 132.91B; Operating income INR 31.85B.

• ▍Revenue INR 132.91B
• ▍Operating income INR 31.85B
• ▍Net margin 22.9%

Revenue INR 126.53B; Operating income INR 30.03B.

• ▍Revenue INR 126.53B
• ▍Operating income INR 30.03B
• ▍Net margin 22.4%

Revenue INR 584.62B, +11,2% YoY; Operating income +2,9% YoY.

• ▍Revenue INR 584.62B, +11,2% YoY
• ▍Operating income +2,9% YoY
• ▍Net income +5,0% YoY
• ▍Free cash flow −15,9% YoY
• ▍Net margin 19.6%

Revenue INR 525.78B, +8,4% YoY; Operating income +18,8% YoY.

• ▍Revenue INR 525.78B, +8,4% YoY
• ▍Operating income +18,8% YoY
• ▍Net income +14,1% YoY
• ▍Free cash flow +10,0% YoY
• ▍Net margin 20.8%

Revenue INR 484.97B, +10,5% YoY; Operating income +10,2% YoY.

• ▍Revenue INR 484.97B, +10,5% YoY
• ▍Operating income +10,2% YoY
• ▍Net income +13,0% YoY
• ▍Free cash flow +9,5% YoY
• ▍Net margin 19.7%

Revenue INR 438.86B, +13,5% YoY; Operating income +154,1% YoY.

• ▍Revenue INR 438.86B, +13,5% YoY
• ▍Operating income +154,1% YoY
• ▍Net income +158,9% YoY
• ▍Free cash flow +242,2% YoY
• ▍Net margin 19.3%